Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.75 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17285659 | 0.92 | PDE10A (0.77) | PDE10ACA12CA9SMN1; SMN2NPC1 | |
| SCHEMBL17285581 | 0.86 | PDE10A (1.00) | PDE10ASMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL10993565 | 0.79 | PDE10A (0.73) | PDE10ASMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL17285632 | 0.78 | PDE10A (0.85) | PDE10ASMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL17275553 | 0.78 | PDE10A (1.00) | PDE10ASMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL12354513 | 0.73 | CA12 (0.66) | PDE10ACA12CA9SMN1; SMN2NPC1 | |
| SCHEMBL10987505 | 0.70 | SMN1; SMN2 (0.62) | PDE10ASMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL10988413 | 0.70 | SMN1; SMN2 (0.58) | PDE10ASMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL172248 | 0.70 | CYP19A1 (0.61) | CA12CA9SMN1; SMN2NPC1RAB9A | |
| SCHEMBL17275587 | 0.70 | PDE10A (1.00) | PDE10ASMN1; SMN2NPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10138245-B2 | Fused triazole derivatives as phosphodiesterase 10A inhibitors | CELON PHARMA S.A. (PL) | 2018-11-27 | — | — | US | disclosed |
| EP-3145930-B1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | Celon Pharma Sa (PL) | 2018-07-04 | — | — | EP | disclosed |
| EP-3145930-B1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | Celon Pharma Sa (PL) | 2018-07-04 | — | — | EP | disclosed |
| US-20170114064-A1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | CELON PHARMA S.A. (PL) | 2017-04-27 | — | — | US | disclosed |
| US-20170114064-A1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | CELON PHARMA S.A. (PL) | 2017-04-27 | — | — | US | disclosed |
| US-20170114064-A1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | CELON PHARMA S.A. (PL) | 2017-04-27 | — | — | US | disclosed |
| WO-2015177688-A1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | CELON PHARMA S.A. (PL) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138245-B2 | Fused triazole derivatives as phosphodiesterase 10A inhibitors | PDE3B, PDE3A, PDE5A | PDE10A 7/4885CA12 4602/4885CA9 1927/4885 |
| US-20170114064-A1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | PDE3B, PDE3A, PDE5A | PDE10A 7/4885CA12 4602/4885CA9 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.